Additionally, treatment with ursodeoxycholic acid (UDCA) enhanced hepatic expression of Nrf2 and increased the protein abundance of the Nrf2 targets Trx and Trxr-1 in patients with primary biliary cirrhosis [60]. Here, NFE2L2 is linked to primary biliary cholangitis.